Drug intelligence / Profile preview

Advaite HDAC6 inhibitor

Development stage: Preclinical
Lead developer: Advaite
Modality: Small Molecules

Overview

Advaite's HDAC6 inhibitor is a preclinical small molecule designed for the treatment of various cancers. Licensed from George Washington University in 2019, this compound selectively inhibits histone deacetylase 6 (HDAC6), an epigenetic regulator involved in tumor growth and immune evasion. A key differentiator of this candidate is its AMES-negative profile, indicating it is non-mutagenic and potentially less toxic than earlier generations of HDAC inhibitors. By selectively targeting HDAC6, the drug aims to slow tumor progression and remodel the tumor microenvironment to enhance immune system recognition and destruction of cancer cells.

Other names: AMES-negative HDAC6 inhibitorNovel AMES Negative HDAC6 Inhibitor Technology

Targets

HDAC6 CD2 (HDAC6 catalytic domain 2)

Beyond the preview

Go deeper on Advaite HDAC6 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advaite HDAC6 inhibitor.

Explore the full profile